A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.

Published

Journal Article

Anti-vascular endothelial growth factor (VEGF) therapies lead to a major breakthrough in treatment of neovascular retinal diseases such as age-related macular degeneration or diabetic retinopathy. Current management of these conditions require regular and frequent intravitreal injections to prevent disease recurrence once the effect of the injected drug wears off. This has led to a pressing clinical need of developing sustained release formulations or therapies with longer duration. A major drawback in developing such therapies is that the currently available animal models show spontaneous regression of vascular leakage. They therefore not only fail to recapitulate retinal vascular disease in humans, but also prevent to discern if regression is due to prolonged therapeutic effect or simply reflects spontaneous healing. Here, we described the development of a novel rabbit model of persistent retinal neovascularization (PRNV). Retinal Müller glial are essential for maintaining the integrity of the blood-retinal barrier. Intravitreal injection of DL-alpha-aminoadipic acid (DL-AAA), a selective retinal glial (Müller) cell toxin, results in persistent vascular leakage for up to 48 weeks. We demonstrated that VEGF concentrations were significantly increased in vitreous suggesting VEGF plays a significant role in mediating the leakage observed. Intravitreal administration of anti-VEGF drugs (e.g. bevacizumab, ranibizumab and aflibercept) suppresses vascular leakage for 8-10 weeks, before recurrence of leakage to pre-treatment levels. All three anti-VEGF drugs are very effective in re-ducing angiographic leakage in PRNV model, and aflibercept demonstrated a longer duration of action compared with the others, reminiscent of what is observed with these drugs in human in the clinical setting. Therefore, this model provides a unique tool to evaluate novel anti-VEGF formulations and therapies with respect to their duration of action in comparison to the currently used drugs.

Full Text

Duke Authors

Cited Authors

  • Li, Y; Busoy, JM; Zaman, BAA; Tan, QSW; Tan, GSW; Barathi, VA; Cheung, N; Wei, JJ-Y; Hunziker, W; Hong, W; Wong, TY; Cheung, CMG

Published Date

  • September 2018

Published In

Volume / Issue

  • 174 /

Start / End Page

  • 98 - 106

PubMed ID

  • 29852133

Pubmed Central ID

  • 29852133

Electronic International Standard Serial Number (EISSN)

  • 1096-0007

Digital Object Identifier (DOI)

  • 10.1016/j.exer.2018.05.027

Language

  • eng

Conference Location

  • England